Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema 2.4 mg/2.4 mg in overweight or obese adults with type 2 diabetes
2021-005121-24Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- May 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and type 2 diabetes mellitus (T2DM) comparing CagriSema 2.4 mg/2.4 mg with Placebo (2 arms). Primary endpoint: Relative change in body weight. Started May 2022; status: active.
02
Drugs
CagriSema
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-005121-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005121-24.